PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

NOVAVAX to Present at the 14th Annual Bio CEO & Investor Conference

ROCKVILLE, Md., Feb. 10, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company, announced today that Frederick W. Driscoll, Vice President and Chief Financial Officer of Novavax, will be presenting at the 14th Annual Bio CEO & Investor Conference in New York on Monday, February 13th at 4:00pm. A live audio-only webcast link for the presentation can be accessed via the company website at www.novavax.com under Investor Info/Events.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle (VLP) and recombinant nanoparticle technology, as well as new and efficient manufacturing approaches, the company produces potent vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India and LG Life Sciences of Korea. Together, these companies have worldwide commercialization capacity and the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website, www.novavax.com.

CONTACT: Frederick W. Driscoll
         VP, Chief Financial Officer and Treasurer
         Novavax, Inc.
         240-268-2000
Novavax, Inc.